pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CD19 · news · pharmadog
← back to CD19
News · CD19
45
stories
17h
nChroma halves workforce, BioXcel lets execs go
biospace
4d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
7d
Kyverna abandons next-gen autoimmune CAR-T once touted as follow-up to miv-cel
fiercebiotech
8d
Biopharma layoffs rise YOY in October but sharply trend down for 2026
biospace
21d
Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials
fiercebiotech
23d
Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy
fiercebiotech
24d
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
fiercebiotech
27d
BMS sheds light on patient death in CAR-T trial, wants to get program back on track
fiercebiotech
28d
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
biospace
29d
Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyout
fiercebiotech
Oct 9, 26
How Abogen went from COVID hype to a $7.8B Novartis deal
biospace
Oct 7, 26
Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up
biospace
Oct 5, 26
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
Oct 5, 26
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
Oct 2, 26
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
biopharma dive
Oct 2, 26
Novartis takes rights to Abogen's mRNA T cell engager for $575M upfront
endpoints
Oct 2, 26
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
fiercebiotech
Oct 1, 26
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
Sep 28, 26
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
fiercebiotech
Sep 25, 26
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
fiercebiotech
Sep 24, 26
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
biospace
Sep 23, 26
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
fiercebiotech
Sep 15, 26
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
biospace
Sep 14, 26
Unlocking cell surface protein research with site-specific labeling
biospace
Sep 3, 26
The hidden scale-out problem behind CAR-T’s growth
biopharma dive
Sep 3, 26
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
fiercebiotech
Sep 1, 26
Roche finds another oncology gem in Asia with $1.5B B cell disease partnership
biospace
Sep 1, 26
Novartis pauses CAR T studies due to 3 deaths; BMS follows suit after safety events
biospace
Sep 1, 26
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
fiercebiotech
Sep 1, 26
Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
endpoints
← prev
page 1 of 2
next →